Analysis of kidney treatment data using the multiFiltratePRO device
Retrospective Data Analysis of CKRT Treatments in Adult Mode with MultiFiltratePRO
This study looks at past treatment data from patients with kidney problems to see how well the multiFiltratePRO device worked for them during their care.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 250 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Fresenius Medical Care Deutschland GmbH Industry-sponsored |
| Locations | 3 sites (Bielefeld, Nordrhein-Westfalen and 2 other locations) |
| Trial ID | NCT06236984 on ClinicalTrials.gov |
What this trial studies
This observational study analyzes retrospective data from patients who received Continuous Kidney Replacement Therapy (CKRT) using the multiFiltratePRO device between January 2015 and January 2024. The study aims to document the treatments provided to patients suffering from Acute Kidney Injury (AKI) and renal failure, reflecting real-world clinical practices. By examining the performance of the multiFiltratePRO system, the study seeks to contribute empirical evidence regarding its effectiveness in treating these conditions.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older who have received CKRT treatment for acute kidney injury or chronic dialysis.
Not a fit: Patients who have participated in interventional clinical studies during the data collection period may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the effectiveness of the multiFiltratePRO device for patients with acute kidney injury.
How similar studies have performed: Other studies have shown success with similar approaches in analyzing retrospective data for kidney treatments, indicating potential for valuable findings.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * All patients with an indication for the extracorporeal blood treatment suffering from AKI who received CKRT adult mode treatment for at least once with: Heparin-Continuous veno-venous hemofiltration Hep-CVVH (Pre CVVH, Post CVVH and Pre-Post CVVH), Heparin-Continuous veno-venous hemodialysis Hep-CVVHD, Heparin-Continuous veno-venous hemodiafiltration Hep-CVVHDF (Pre-CVVHDF and Post-CVVHDF), Citrate-Calcium(Ci-Ca)-CVVHD, Citrate-Calcium(Ci-Ca) CVVHDF, between January 2015 and January 2024, with the investigational device, have to be included in the study in chronological order. * No age restriction for heparin modes * Age ≥ 18 years for Ci-Ca modes at treatment start * Patient´s body weight ≥ 40kg irrespective of age * Acute Kidney Injury (AKI) OR chronic dialysis patients with clinical indication for CKRT Exclusion Criteria: * Participation in an interventional clinical study during the retrospectively collected CKRT treatment data * Previous participation in the same study * No study-specific exclusion criteria based on contraindications due to the retrospective character of the study
Where this trial is running
Bielefeld, Nordrhein-Westfalen and 2 other locations
- Evangelisches Klinikum Bethel gGmbH Universitätsklinikum OWL der Universität Bielefeld — Bielefeld, Nordrhein-Westfalen, Germany (Recruiting)
- Klinikum Leverkusen gGmbH — Leverkusen, Nordrhein-Westfalen, Germany (Recruiting)
- Klinikum Ludwigshafen — Ludwigshafen, Rheinland-Pfalz, Germany (Recruiting)
Study contacts
- Principal investigator: Rainer Borgstedt, Dr. med. — Evangelisches Klinikum Bethel gGmbH Universitätsklinikum OWL der Universität Bielefeld
- Study coordinator: Manuela Stauss-Grabo, Dr.
- Email: manuela.stauss-grabo1@freseniusmedicalcare.com
- Phone: +49 1525 469 1929
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.